June 16, 2021 08:15 AM EDT
Deals
Pharma

Amid slug­gish sales and du­el­ing law­suits, No­var­tis bows out of Am­gen part­ner­ship, slash­es staff

Jason Mast

Editor

When No­var­tis and Am­gen got Aimovig ap­proved in 2018, most mi­graine pa­tients re­lied on decades-old, mild­ly ef­fec­tive pills to ease their headaches. Proven to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times